Sanofi has started a Phase II/III clinical trial of rheumatoid arthritis drug Kevzara (sarilumab) to treat patients hospitalised with severe Covid-19 infection outside of the US.
The first participant in the study, which is being conducted in Italy, Spain, Germany, France, Canada and Russia, has already been treated.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Sanofi’s partner, Regeneron Pharmaceuticals, is responsible for performing the study’s counterpart in the US, which commenced earlier this month.
